Trials / Conditions / Schizophreniform Disorder

Schizophreniform Disorder

72 registered clinical trials studyying Schizophreniform Disorder — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Cognitive Strategies in Early Psychosis 2 NCT07263022	University of Minnesota	Phase 3
Recruiting	Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Epi NCT05890183	University of California, Los Angeles	N/A
Unknown	Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia NCT02533232	Pakistan Institute of Living and Learning	Phase 1
Completed	The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia NCT04013555	University of Maryland, Baltimore	Phase 1 / Phase 2
Terminated	Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode NCT04203056	University of California, Los Angeles	Phase 4
Completed	Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life NCT03757988	University of North Carolina, Chapel Hill	N/A
Completed	Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 NCT03201757	Alkermes, Inc.	Phase 3
Completed	Enhancing Cognitive Training Through Exercise Following a First Schizophrenia Episode NCT02823041	University of California, Los Angeles	N/A
Withdrawn	Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia NCT03061136	Palo Alto Veterans Institute for Research	Phase 4
Completed	Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder NCT03043820	Iris Sommer	Phase 3
Completed	RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia) NCT02160249	London School of Hygiene and Tropical Medicine	N/A
Completed	Electronic Cigarettes in Smokers With Mental Illness NCT02212041	King's College London	N/A
Completed	Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis NCT02566057	Northwell Health	N/A
Terminated	Prednisolone Addition for Patients With Recent-onset Psychotic Disorder NCT02949232	UMC Utrecht	Phase 4
Completed	Integrated Metacognitive Therapy in First Episode Psychosis NCT02131116	Indiana University	N/A
Completed	rTMS in First Episode Psychosis NCT02131129	Indiana University	N/A
Completed	Pilot-trial of Emotion-focused Cognitive Behavior Therapy for Patients With Schizophrenia NCT02787122	Philipps University Marburg	N/A
Unknown	Association of Amisulpride Response in Schizophrenia With Brain Image NCT02095938	CHA University	Phase 4
Completed	RCT of Methotrexate Added to Treatment As Usual in Schizophrenia NCT02074319	Pakistan Institute of Living and Learning	Phase 1
Completed	Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode NCT02267070	University of California, Los Angeles	N/A
Completed	Simvastatin Addition for Patients With Recent-onset Schizophrenia NCT01999309	Iris Sommer	Phase 3
Completed	Naltrexone for Antipsychotic-Induced Weight Gain NCT01866098	Yale University	N/A
Completed	Effectiveness of Adherence Therapy for Schizophrenia NCT01780116	The Hong Kong Polytechnic University	Phase 1 / Phase 2
Completed	Omega-3 Dietary Supplements in Schizophrenia NCT01786239	Delbert Robinson	N/A
Terminated	Antipsychotic Effects on Brain Function in Schizophrenia NCT01913327	University of California, San Francisco	Phase 4
Terminated	Contrasting Group Therapy Methods for Psychosis NCT01764568	University of British Columbia	N/A
Completed	Lifestyle Intervention for Diabetes and Weight Management in Psychosis NCT01828931	Centre for Addiction and Mental Health	N/A
Completed	Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents NCT01731119	University of North Carolina, Chapel Hill	Phase 2
Completed	Biomarkers in First Episode Schizophrenia NCT02033382	NYU Langone Health	—
Completed	Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia NCT02137993	HK inno.N Corporation	Phase 4
Completed	Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia NCT01481883	The Alfred	Phase 4
Completed	Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen NCT01555814	Birte Glenthoj	N/A
Completed	Optimization of Treatment and Management of Schizophrenia in Europe NCT01248195	Rene Kahn	Phase 4
Completed	Brain Circuits in Schizophrenia and Smoking NCT01425684	University of Maryland, Baltimore	—
Completed	Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States NCT01425671	University of Maryland, Baltimore	—
Completed	Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis NCT01216891	Research Foundation for Mental Hygiene, Inc.	N/A
Completed	Randomized Double Blind Placebo Control Study in Patients with Schizophrenia NCT01602029	Pakistan Institute of Living and Learning	Phase 2
Completed	An Integrated Program for the Treatment of First Episode of Psychosis NCT01321177	Northwell Health	N/A
Completed	Prevention of Weight Gain in Early Psychoses NCT01075295	Centre for Addiction and Mental Health	N/A
Completed	DECIFER: Depression and Citalopram In First Episode Recovery NCT01041274	NYU Langone Health	Phase 4
Completed	Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia NCT01029769	Technical University of Munich	N/A
Completed	Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study NCT01269710	University of North Carolina, Chapel Hill	—
Completed	Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia. NCT00716755	Centre for Addiction and Mental Health	N/A
Completed	Role of Anti-Inflammatory Agents in Patients With Schizophrenia NCT00929955	Pakistan Institute of Living and Learning	Phase 1
Completed	Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia NCT00847600	Sha'ar Menashe Mental Health Center	Phase 4
Unknown	Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia NCT00825045	Centre for Addiction and Mental Health	N/A
Completed	Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral Therapy NCT00791440	New York State Psychiatric Institute	N/A
Terminated	Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects NCT00734435	Orexigen Therapeutics, Inc	Phase 2
Terminated	Schizophrenic Patients in Integrated Care NCT00681629	AstraZeneca	Phase 4
Completed	Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain NCT00709202	Nathan Kline Institute for Psychiatric Research	Phase 2
Completed	Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Sch NCT00749970	AstraZeneca	—
Unknown	A German Multicenter Study on Toxoplasma Gondii in First-episode Schizophrenia NCT00686400	Martin-Luther-Universität Halle-Wittenberg	—
Completed	An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schiz NCT01855074	Janssen-Cilag Ltd.	Phase 4
Terminated	Anticholinergic Burden in Schizophrenia NCT00715377	Centre for Addiction and Mental Health	N/A
Unknown	Donepezil Double Blind Trial for ECT Memory Disfunction NCT00465283	BeerYaakov Mental Health Center	Phase 4
Unknown	Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Ps NCT00465920	University of Cologne	Phase 2
Completed	Varenicline Adjunctive Treatment in Schizophrenia NCT00492349	University of Maryland, Baltimore	Phase 4
Unknown	Integrated Care in Psychotic Disorders With Severe Mental Illness NCT01888627	Universitätsklinikum Hamburg-Eppendorf	N/A
Completed	Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia NCT00361543	The Alfred	Phase 4
Completed	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications. NCT00391261	Cambridge Health Alliance	Phase 4
Completed	Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia NCT00337662	Eli Lilly and Company	Phase 4
Completed	Open-label Ziprasidone Study for Psychosis Treatment in Adolescents NCT00421954	New York State Psychiatric Institute	Phase 3
Terminated	Optimizing Response in Psychosis Study NCT00314327	Northwell Health	Phase 4
Completed	Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and NCT00312598	University of North Carolina, Chapel Hill	—
Completed	PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders NCT00399334	Janssen-Cilag, S.A.	—
Completed	Study of Amantadine for Weight Stabilization During Olanzapine Treatment NCT00287352	University of North Carolina, Chapel Hill	Phase 1
Completed	Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia NCT00434980	Beth Israel Deaconess Medical Center	N/A
Completed	A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosi NCT00246259	Janssen-Ortho Inc., Canada	Phase 4
Completed	The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study NCT00206557	The Alfred	Phase 2
Terminated	Study on the Safety of Risperidone on Obese or Overweight Patients With Schizophrenia NCT00511628	Janssen-Cilag, S.A.	—
Completed	Clinical Trial of Dipyridamole in Schizophrenia NCT00349973	University of Maryland, Baltimore	N/A
Completed	Clinical Estradiol Trial in Women With Schizophrenia NCT00206570	Bayside Health	Phase 2